{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer+Disease+1&page=3",
    "query": {
      "condition": "Alzheimer Disease 1",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 106,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer+Disease+1&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer+Disease+1&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T09:25:58.127Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02727699",
      "title": "A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dementia, Alzheimer Type"
      ],
      "interventions": [
        {
          "name": "Xanamem™",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for Xanamem™)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actinogen Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 185,
      "start_date": "2017-03-23",
      "completion_date": "2019-03-15",
      "has_results": true,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-10-06T09:25:58.127Z",
      "location_count": 14,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Poway, California + 11 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02727699"
    },
    {
      "nct_id": "NCT07142278",
      "title": "DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Alzheimer Disease (AD)",
        "Preclinical Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "DUVAX 200 µg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DUVAX 400 µg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Adjuvant only)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Nuravax, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "40 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2026-09-25",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-06T09:25:58.127Z",
      "location_count": 1,
      "location_summary": "Miami Lakes, Florida",
      "locations": [
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07142278"
    },
    {
      "nct_id": "NCT06356337",
      "title": "A Light Exposure Tracker Designed to Improve Circadian Rhythms - Aim 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Light goggles",
          "type": "DEVICE"
        },
        {
          "name": "Daily reminder test message",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BEHAVIORAL"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-02-22",
      "completion_date": "2024-08-15",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-10-06T09:25:58.127Z",
      "location_count": 1,
      "location_summary": "Menands, New York",
      "locations": [
        {
          "city": "Menands",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06356337"
    },
    {
      "nct_id": "NCT05408780",
      "title": "A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "AC-OLE-01-VA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cerecin",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 45,
      "start_date": "2022-07-14",
      "completion_date": "2022-10-24",
      "has_results": false,
      "last_update_posted_date": "2023-10-17",
      "last_synced_at": "2026-10-06T09:25:58.127Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05408780"
    },
    {
      "nct_id": "NCT05637801",
      "title": "A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Alzheimer Disease 1",
        "Alzheimer Disease 2",
        "Alzheimer Disease 3",
        "Alzheimer Disease, Early Onset",
        "Alzheimer Disease, Late Onset",
        "Alzheimer Disease 9",
        "Alzheimer Disease 4",
        "Alzheimer Disease 7",
        "Alzheimer Disease 17",
        "Alzheimer's Dementia Late Onset",
        "Alzheimer Disease 5",
        "Alzheimer Disease 6",
        "Alzheimer Disease 8",
        "Alzheimer Disease 10",
        "Alzheimer Disease 11",
        "Alzheimer Disease 12",
        "Alzheimer Disease 13",
        "Alzheimer Disease 14",
        "Alzheimer Disease 15",
        "Alzheimer Disease 16",
        "Alzheimer Disease 18",
        "Alzheimer Disease 19",
        "Dementia",
        "Dementia Alzheimers",
        "Dementia, Mild",
        "Dementia of Alzheimer Type",
        "Dementia Moderate",
        "Dementia Senile",
        "Mild Cognitive Impairment",
        "Mild Dementia",
        "MCI",
        "Cognitive Impairment",
        "Cognitive Decline",
        "Cognitive Impairment, Mild"
      ],
      "interventions": [
        {
          "name": "Spectris™ AD - Active",
          "type": "DEVICE"
        },
        {
          "name": "Spectris™ AD - Sham",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cognito Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 673,
      "start_date": "2022-12-13",
      "completion_date": "2026-08-17",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-06T09:25:58.127Z",
      "location_count": 68,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05637801"
    },
    {
      "nct_id": "NCT01209156",
      "title": "Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "[18F] PBR111",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institute for Neurodegenerative Disorders",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2010-03",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2013-11-11",
      "last_synced_at": "2026-10-06T09:25:58.127Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01209156"
    },
    {
      "nct_id": "NCT03702816",
      "title": "The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Parkinson Disease",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "GE180 PET Scan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aaron Ritter, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 24,
      "start_date": "2018-12-13",
      "completion_date": "2019-09-29",
      "has_results": true,
      "last_update_posted_date": "2023-05-24",
      "last_synced_at": "2026-10-06T09:25:58.127Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03702816"
    },
    {
      "nct_id": "NCT01443936",
      "title": "Experimental AD4-H5-VTN Vaccine in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "H5N1 Influenza"
      ],
      "interventions": [
        {
          "name": "Ad4-H5-VTN vaccination-tonsillar route",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad4-H5-vaccination-oral route",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 96,
      "start_date": "2011-09-14",
      "completion_date": "2019-04-24",
      "has_results": false,
      "last_update_posted_date": "2019-12-16",
      "last_synced_at": "2026-10-06T09:25:58.127Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01443936"
    },
    {
      "nct_id": "NCT05696483",
      "title": "Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "OLX-07010 Active",
          "type": "DRUG"
        },
        {
          "name": "OLX-07010 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oligomerix, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 76,
      "start_date": "2023-01-20",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-06T09:25:58.127Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05696483"
    },
    {
      "nct_id": "NCT01035138",
      "title": "A Study of Semagacestat for Alzheimer's Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "semagacestat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2009-12",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2014-09-25",
      "last_synced_at": "2026-10-06T09:25:58.127Z",
      "location_count": 41,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 38 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01035138"
    }
  ]
}